CD274 and non-small cell lung carcinoma: The combination of immunotherapy and chemotherapy is now integrated as a standard of care in the first-line treatment setting of NSCLC.103 Although such combinations result in improved response rates, PFS and OS (regardless of PD-L1 status) compared with chemotherapy only, the toxicity rates are higher.